235 related articles for article (PubMed ID: 15598944)
1. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
Gervais R; Ducolone A; Breton JL; Braun D; Lebeau B; Vaylet F; Debieuvre D; Pujol JL; Tredaniel J; Clouet P; Quoix E
Ann Oncol; 2005 Jan; 16(1):90-6. PubMed ID: 15598944
[TBL] [Abstract][Full Text] [Related]
2. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Quoix E; Lebeau B; Depierre A; Ducolone A; Moro-Sibilot D; Milleron B; Breton JL; Lemarie E; Pujol JL; Brechot JM; Zalcman G; Debieuvre D; Vaylet F; Vergnenegre A; Clouet P
Ann Oncol; 2004 Jan; 15(1):38-44. PubMed ID: 14679117
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
[TBL] [Abstract][Full Text] [Related]
4. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00).
Vázquez S; Grande C; Amenedo M; Fírvida JL; Lázaro M; Alonso G; Curiel T; Huidobro G; Mel JR; Ramos M
Anticancer Drugs; 2004 Jun; 15(5):489-94. PubMed ID: 15166623
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
[TBL] [Abstract][Full Text] [Related]
6. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
Douillard JY; Gervais R; Dabouis G; Le Groumellec A; D'Arlhac M; Spaeth D; Coudert B; Caillaud D; Monnier A; Clary C; Maury B; Mornet M; Rivière A; Clouet P; Couteau C
Ann Oncol; 2005 Jan; 16(1):81-9. PubMed ID: 15598943
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
Camps C; Massuti B; Jiménez A; Maestu I; Gómez RG; Isla D; González JL; Almenar D; Blasco A; Rosell R; Carrato A; Viñolas N; Batista N; Girón CG; Galán A; López M; Blanco R; Provencio M; Diz P; Felip E;
Ann Oncol; 2006 Mar; 17(3):467-72. PubMed ID: 16371411
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Esteban E; González de Sande L; Fernández Y; Corral N; Fra J; Muñiz I; Vieitez JM; Palacio I; Fernández JL; Estrada E; Lacave AJ;
Ann Oncol; 2003 Nov; 14(11):1640-7. PubMed ID: 14581272
[TBL] [Abstract][Full Text] [Related]
9. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
10. Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
Valerio MR; Russo A; Latteri MA; Modica G; Gulotta G; Armata MG; Bajardi E; Cicero G; Pantuso G; Grassi N; Agosta G; Gebbia N
Lung Cancer; 2001 Dec; 34 Suppl 4():S31-5. PubMed ID: 11742700
[TBL] [Abstract][Full Text] [Related]
11. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Tabernero J; Climent MA; Lluch A; Albanell J; Vermorken JB; Barnadas A; Antón A; Laurent C; Mayordomo JI; Estaun N; Losa I; Guillem V; Garcia-Conde J; Tisaire JL; Baselga J
Ann Oncol; 2004 Sep; 15(9):1358-65. PubMed ID: 15319242
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
Niho S; Ohe Y; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Goto K; Nishiwaki Y
Lung Cancer; 2002 Feb; 35(2):209-14. PubMed ID: 11804695
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TC; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
J Clin Oncol; 2004 May; 22(9):1589-97. PubMed ID: 15117980
[TBL] [Abstract][Full Text] [Related]
18. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Ardizzoia A; Acquati M; Fagnani D; Giordano M; Visini M; Scanni A; Quattrone A; Fusco O; Vergani C; Casartelli C; Tagliabue P; Malugani F;
Lung; 2004; 182(1):1-8. PubMed ID: 14752667
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
Lilenbaum R; Rubin M; Samuel J; Boros L; Chidiac T; Seigel L; Dowlati A; Graham P; Beaumont J; Du H
J Thorac Oncol; 2007 Apr; 2(4):306-11. PubMed ID: 17409802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
